Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving beta-blockers: Insights from the BEST trialDESAI, Ravi V; GUICHARD, Jason L; ABAN, Inmaculada B et al.International journal of cardiology. 2013, Vol 163, Num 1, pp 61-67, issn 0167-5273, 7 p.Article

β-Adrenergic receptor blockade in chronic heart failureBRISTOW, M. R.Circulation (New York, N.Y.). 2000, Vol 101, Num 5, pp 558-569, issn 0009-7322Article

Partial agonist activity of bucindolol is dependent on the activation state of the human β₁-Adrenergic receptorMAACK, Christoph; BÖHM, Michael; VLASKIN, Lydia et al.Circulation (New York, N.Y.). 2003, Vol 108, Num 3, pp 348-353, issn 0009-7322, 6 p.Article

Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with β-blockade in patients with heart failure: The β-Blocker Evaluation of Survival Trial (BEST)EICHHORN, Eric J; GRAYBURN, Paul A; KRAUSE-STEINRAUF, Heidi et al.Circulation (New York, N.Y.). 2003, Vol 108, Num 19, pp 2336-2341, issn 0009-7322, 6 p.Article

Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failureTAYLOR, Matthew R. G; SLAVOV, Dobromir; HUMPHREY, Kurt et al.Pharmacogenetics and genomics (Print). 2009, Vol 19, Num 1, pp 35-43, issn 1744-6872, 9 p.Article

Antihypertensive drugsDEITCHMAN, D; LABUDDE, J. A; SEIDEHAMEL, R. J et al.New drugs annual: cardiovascular drugs. 1983, Vol 1, pp 1-67Article

Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardiumBRIXIUS, Klara; BUNDKIRCHEN, Andreas; BÖLCK, Birgit et al.British journal of pharmacology. 2001, Vol 133, Num 8, pp 1330-1338, issn 0007-1188Article

Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapyO'CONNOR, Christopher M; GOTTLIEB, Steven; BOURQUE, Jamieson M et al.The American journal of cardiology. 2005, Vol 95, Num 5, pp 558-564, issn 0002-9149, 7 p.Article

Quantitative determination of bucindolol concentration in intact gel capsules using Raman spectroscopyNIEMCZYK, T. M; DELGADO-LOPEZ, M. M; ALLEN, F. S et al.Analytical chemistry (Washington, DC). 1998, Vol 70, Num 13, pp 2762-2765, issn 0003-2700Article

A review of why and how we may use β-blockers in congestive heart failureCONSTANT, J.Chest. 1998, Vol 113, Num 3, pp 800-808, issn 0012-3692Article

Importance of a history of hypertension for the prognosis after Acute myocardial infarction: for the Bucindolol Evaluation in Acute myocardial infarction Trial (BEAT) study groupALI, Irma; AKMAN, Dilek; BRUUN, Niels Eske et al.Clinical cardiology (Mahwah, NJ). 2004, Vol 27, Num 5, pp 265-269, issn 0160-9289, 5 p.Article

Beta-adrenergic blocker mortality trials in congestive heart failureTEERLINK, J. R; MASSIE, B. M.The American journal of cardiology. 1999, Vol 84, Num 9A, pp 94R-102R, issn 0002-9149Article

The effect of β-blockers on health-related quality of life in patients with heart failureREDDY, P; DUNN, A. B.Pharmacotherapy. 2000, Vol 20, Num 6, pp 679-689, issn 0277-0008Article

Comparison of the beta blocker Bucindolol in younger versus older patients with heart failureARANDA, Juan M; KRAUSE-STEINRAUF, Heidi J; GREENBERG, Barry H et al.The American journal of cardiology. 2002, Vol 89, Num 11, pp 1322-1326, issn 0002-9149Article

Current role of β-adrenergic blockers in the treatment of chronic congestive heart failureSMITH, Andrew J; WEHNER, Jessica S; MANLEY, Harold J et al.American journal of health-system pharmacy. 2001, Vol 58, Num 2, pp 140-145, issn 1079-2082Article

The role of third-generation beta-blocking agents in chronic heart failureBRISTOW, M. R; RODEN, R. L; LOWES, B. D et al.Clinical cardiology. Supplement (Mahwah, NJ). 1998, Vol 21, Num 12, pp I.3-I.13, 1Conference Paper

Second- and third-generation beta-blocking drugs in chronic heart failureBRISTOW, M. R; ABRAHAM, W. T; YOSHIKAWA, T et al.Cardiovascular drugs and therapy. 1997, Vol 11, pp 291-296, issn 0920-3206, SUP1Conference Paper

Bucindolol displays intrinsic sympathomimetic activity in human myocardiumANDREKA, Peter; AIYAR, Nambi; OLSON, Leslie C et al.Circulation (New York, N.Y.). 2002, Vol 105, Num 20, pp 2429-2434, issn 0009-7322Article

Effect of selective versus nonselective beta blockade on qt dispersion in patients with nonischemic dilated cardiomyopathyFESMIRE, S. I; MARCOUX, L. G; LYYSKI, D. S et al.The American journal of cardiology. 1999, Vol 84, Num 3, pp 350-354, issn 0002-9149Article

The effect of Diabetes on outcomes of Patients with advanced heart failure in the BEST trialDOMANSKI, Michael; KRAUSE-STEINRAUF, Heidi; MARTIN, Wade et al.Journal of the American College of Cardiology. 2003, Vol 42, Num 5, pp 914-922, issn 0735-1097, 9 p.Article

Β-adrenoceptor antagonists in elderly patients with chronic heart failure : Therapeutic potential of third-generation agentsCOATS, Andrew J. S.Drugs & aging. 2006, Vol 23, Num 2, pp 93-99, issn 1170-229X, 7 p.Article

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failureThe New England journal of medicine. 2001, Vol 344, Num 22, pp 1659-1667, issn 0028-4793Article

The pharmacokinetics of bucindolol and its major metabolite in essential hypertensionMEREDITH, P. A; KELMAN, A. W; MCSHARRY, D. R et al.Xenobiotica (London. Print). 1985, Vol 15, Num 11, pp 979-985, issn 0049-8254Article

Pharmacology of combined α-β-blockade ILOUIS, W. J; MCNEIL, J. J; DRUMMER, O. H et al.Drugs (Basel). 1984, Vol 28, pp 16-34, issn 0012-6667, suppl. 2Article

Comparative β-adrenoceptor blocking effect and pharmacokinetics of bucindolol and propranolol in manMAURY, M; BERDEAUX, A; KHER, A et al.European journal of clinical pharmacology. 1985, Vol 27, Num 6, pp 649-656, issn 0031-6970Article